

AMENDMENTS TO THE CLAIMS:

Please amend the claims as follows:

1. (Currently Amended) A method for producing a biological platform containing a pharmacologically active coating, said method comprising applying to at least a portion of a surface of a biological platform an inhibitor of synthesis of an extracellular matrix, of cell proliferation and migration, and of inflammation, to produce said biological platform containing a pharmacologically active coating, said inhibitor being a decorin peptide or biologically active fragment of decorin selected from the group consisting of (a) a decorin peptide comprising signal peptide and propeptide, (b) a 15-20 kDa biologically active fragment of decorin comprising amino acids 115 to 260 of decorin, (c) a biologically active fragment of decorin comprising a leucine-rich repeat, protein core (38-43 kDa) sequence of decorin and (d) a biologically active fragment of decorin comprising a decorin loop structure formed from cysteine residues.

2. (Currently Amended) A method for producing a biological platform containing a pharmacologically active coating, said method comprising applying to at least a portion of a surface of a biological platform an inhibitor of synthesis of an extracellular matrix, of cell proliferation and migration, and of inflammation, to produce said biological platform containing a pharmacologically active coating, said inhibitor being a decorin peptide or biologically active fragment of decorin selected from the group consisting of (a) a decorin peptide comprising signal peptide and propeptide, (b) a 15-20 kDa biologically active fragment of decorin comprising amino acids 115 to 260 of decorin, (c) a biologically active fragment of decorin comprising a leucine-rich repeat, protein core

(38-43 kDa) sequence of decorin (d) a biologically active fragment of decorin comprising a decorin loop structure formed from cysteine residues, (e) a chemically modified derivative of (a) which is biologically active, (f) a chemically modified derivative of (b) which is biologically active, (g) a chemically modified derivative of (c) which is biologically active, and (h) a chemically modified derivative of (d) which is biologically active.

Claim 3. (Canceled)

4. (Currently Amended) An endoluminal prostheses comprising a surface coating of a therapeutically effective quantity of a decorin peptide or biologically active fragment of decorin selected from the group consisting of (a) a decorin peptide comprising signal peptide and propeptide, (b) a 15-20 kDa biologically active fragment of decorin comprising amino acids 115 to 260 of decorin, (c) a biologically active fragment of decorin comprising a leucine-rich repeat, protein core (38-43 kDa) sequence of decorin and (d) a biologically active fragment of decorin comprising a decorin loop structure formed from cysteine residues.

5. (Currently Amended) A stent comprising a surface coating of a therapeutically effective quantity of a decorin peptide or biologically active fragment of decorin selected from the group consisting of (a) a decorin peptide comprising signal peptide and propeptide, (b) a 15-20 kDa biologically active fragment of decorin comprising amino acids 115 to 260 of decorin, (c) a biologically active fragment of decorin comprising a leucine-rich repeat, protein core (38-43 kDa) sequence of decorin and (d) a biologically

active fragment of decorin comprising a decorin loop structure formed from cysteine residues.

6. (Previously Presented) The method of claim 1 wherein said biological platform is a prosthesis.

7. (Previously Presented) The method of claim 2 wherein said biological platform is a prosthesis.

8. (Currently Amended) An endoluminal prostheses comprising a surface coating of a therapeutically effective quantity of a decorin peptide or biologically active fragment of decorin selected from the group consisting of (a) a decorin peptide comprising signal peptide and propeptide, (b) a 15-20 kDa biologically active fragment of decorin comprising amino acids 115 to 260 of decorin, (c) a biologically active fragment of decorin comprising a leucine-rich repeat, protein core (38-43 kDa) sequence of decorin (d) a biologically active fragment of decorin comprising a decorin loop structure formed from cysteine residues, (e) a chemically modified derivative of (a) which is biologically active, (f) a chemically modified derivative of (b) which is biologically active, (g) a chemically modified derivative of (c) which is biologically active, and (h) a chemically modified derivative of (d) which is biologically active.

9. (Currently Amended) A stent comprising a surface coating of a therapeutically effective quantity of a decorin peptide or biologically active fragment of decorin selected from the group consisting of (a) a decorin peptide comprising signal peptide and propeptide, (b) a 15-20 kDa biologically active fragment of decorin comprising amino acids 115 to 260 of decorin, (c) a biologically active fragment of decorin comprising a

LAFONT et al.
Appl. No. 10/561,238
Atty. Ref.: 1721-108
Amendment
October 21, 2009

leucine-rich repeat, protein core (38-43 kDa), sequence of decorin (d) a biologically active fragment of decorin comprising a decorin loop structure formed from cysteine residues, (e) a chemically modified derivative of (a) which is biologically active, (f) a chemically modified derivative of (b) which is biologically active, (g) a chemically modified derivative of (c) which is biologically active, and (h) a chemically modified derivative of (d) which is biologically active.